

THERAPEUTIC AGENTS FOR ACHONDROPLASIA

ABSTRACT OF THE DISCLOSURE

The present invention aims to provide novel
5 therapeutic agents for achondroplasia caused by mutations
in FGFR3.

Therapeutic agents for achondroplasia caused by the
cartilage growth inhibition resulting from mutations in the
gene for fibroblast growth factor receptor 3 (FGFR3),
10 comprising a substance activating guanylyl cyclase B (GC-B)
as an active ingredient are disclosed.